Lepu Biopharma Co. Ltd. Class H (2157) Stock Statistics & Valuation Metrics

Lepu Biopharma Co. Ltd. Class H has a market cap or net worth of HK$9.20B. The enterprise value is HK$8.22B.

Lepu Biopharma Co. Ltd. Class H has 1,804,439,800 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lepu Biopharma Co. Ltd. Class H’s return on equity (ROE) is 0.18 and return on invested capital (ROIC) is 3.18%.

The current PE Ratio of Lepu Biopharma Co. Ltd. Class H is 9.3. Lepu Biopharma Co. Ltd. Class H’s PEG ratio is -0.19.

In the last 12 months, Lepu Biopharma Co. Ltd. Class H had revenue of 910.67M and earned 254.60M in profits. Earnings per share was 0.14.

In the last 12 months, operating cash flow was -70.56M and capital expenditures -13.69M, giving a free cash flow of -84.26M billion.

Lepu Biopharma Co. Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―

Lepu Biopharma Co. Ltd. Class H upcoming earnings date is Aug 26, 2026, TBA (Confirmed).

Lepu Biopharma Co. Ltd. Class H as a current ratio of 0.98, with Debt / Equity ratio of 76.32%

In the past 12 months, Lepu Biopharma Co. Ltd. Class H has paid 1.70M in taxes.

Lepu Biopharma Co. Ltd. Class H EV to EBITDA ratio is 44.98, with an EV/FCF ratio of -97.11.

Lepu Biopharma Co. Ltd. Class H has HK$959.17M in cash and marketable securities with HK$1.06B in debt, giving a net cash position of -HK$99.36M billion.

Gross margin is 85.51%, with operating margin of 9.60%, and net profit margin of 27.96%.

The average price target for Lepu Biopharma Co. Ltd. Class H is HK$8.10, which is 11.43% higher than the current price. The consensus rating is Moderate Buy